LPS interactions with immobilized and soluble antimicrobial peptides

Area of Science:

• Biochemistry
• Immunology
• Pharmacology

Background:

• Sepsis therapy can be enhanced by antimicrobial peptides (AMPs) that bind and neutralize lipopolysaccharide (LPS).
• Systemic administration of AMPs can cause toxicity due to non-specific lysis of mammalian cells.
• Extracorporeal therapy using immobilized AMPs offers a potential solution to mitigate toxicity while retaining efficacy.

Purpose of the Study:

• To compare the efficacy of different AMPs in neutralizing LPS when in solution versus immobilized on solid phases.
• To evaluate the ability of immobilized AMPs to neutralize LPS-induced cytokine release in whole blood.
• To assess LPS binding capabilities of various AMPs in both solution and immobilized states.

Main Methods:

• AMPs, including truncated derivatives of LL-37, SC4, BPI, S3 Delta, and CEME, were immobilized using biomolecular interaction analysis and Pierce SulfoLink Coupling Gel.
• Lipopolysaccharide (LPS) binding was assessed using the Limulus Amebocyte Lysate (LAL) test.
• LPS-induced cytokine production (TNF-alpha, IL-1 beta, IL-6) was measured via ELISA after whole blood incubation with LPS and AMPs.

Main Results:

• Immobilization of AMPs did not significantly inhibit their capacity to neutralize LPS.
• Peptides derived from LL-37 and CEME exhibited greater efficiency in both LPS binding and neutralizing LPS-induced cytokine production compared to others.
• Differences in efficacy were observed among the various AMPs tested.

Conclusions:

• Immobilized antimicrobial peptides retain their ability to neutralize LPS and mitigate LPS-induced inflammatory responses.
• AMPs derived from LL-37 and CEME are particularly effective candidates for developing immobilized extracorporeal therapies for sepsis.
• Extracorporeal therapy with immobilized AMPs presents a viable strategy to enhance sepsis treatment while minimizing systemic toxicity.